X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs TORRENT PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES TORRENT PHARMA PIRAMAL ENTERPRISES/
TORRENT PHARMA
 
P/E (TTM) x 36.6 27.2 134.2% View Chart
P/BV x 3.0 5.2 58.7% View Chart
Dividend Yield % 0.8 1.1 76.2%  

Financials

 PIRAMAL ENTERPRISES   TORRENT PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
TORRENT PHARMA
Mar-17
PIRAMAL ENTERPRISES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs2,0951,768 118.5%   
Low Rs1,0251,186 86.5%   
Sales per share (Unadj.) Rs492.8346.1 142.4%  
Earnings per share (Unadj.) Rs72.655.2 131.5%  
Cash flow per share (Unadj.) Rs94.773.3 129.2%  
Dividends per share (Unadj.) Rs21.0014.00 150.0%  
Dividend yield (eoy) %1.30.9 142.0%  
Book value per share (Unadj.) Rs862.5257.1 335.5%  
Shares outstanding (eoy) m172.56169.22 102.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.24.3 74.2%   
Avg P/E ratio x21.526.8 80.3%  
P/CF ratio (eoy) x16.520.1 81.8%  
Price / Book Value ratio x1.85.7 31.5%  
Dividend payout %28.925.4 114.1%   
Avg Mkt Cap Rs m269,194249,887 107.7%   
No. of employees `0004.011.8 34.1%   
Total wages/salary Rs m17,9399,934 180.6%   
Avg. sales/employee Rs Th21,190.34,971.5 426.2%   
Avg. wages/employee Rs Th4,470.1843.2 530.1%   
Avg. net profit/employee Rs Th3,120.0792.4 393.7%   
INCOME DATA
Net Sales Rs m85,03758,569 145.2%  
Other income Rs m2,3382,233 104.7%   
Total revenues Rs m87,37460,802 143.7%   
Gross profit Rs m34,99113,773 254.1%  
Depreciation Rs m3,8173,069 124.4%   
Interest Rs m20,3102,056 988.0%   
Profit before tax Rs m13,20210,881 121.3%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2811,545 147.6%   
Profit after tax Rs m12,5209,336 134.1%  
Gross profit margin %41.123.5 175.0%  
Effective tax rate %17.314.2 121.7%   
Net profit margin %14.715.9 92.4%  
BALANCE SHEET DATA
Current assets Rs m87,59053,841 162.7%   
Current liabilities Rs m185,57831,612 587.1%   
Net working cap to sales %-115.238.0 -303.6%  
Current ratio x0.51.7 27.7%  
Inventory Days Days3197 31.9%  
Debtors Days Days4884 56.8%  
Net fixed assets Rs m108,52342,079 257.9%   
Share capital Rs m345846 40.8%   
"Free" reserves Rs m148,48142,655 348.1%   
Net worth Rs m148,82643,501 342.1%   
Long term debt Rs m144,95722,408 646.9%   
Total assets Rs m482,394101,250 476.4%  
Interest coverage x1.76.3 26.2%   
Debt to equity ratio x1.00.5 189.1%  
Sales to assets ratio x0.20.6 30.5%   
Return on assets %6.811.3 60.5%  
Return on equity %8.421.5 39.2%  
Return on capital %12.019.6 60.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00120,066 74.8%   
Fx outflow Rs m5,1505,304 97.1%   
Net fx Rs m9,85114,762 66.7%   
CASH FLOW
From Operations Rs m-100,39310,127 -991.3%  
From Investments Rs m-24,202-7,869 307.6%  
From Financial Activity Rs m135,705-1,918 -7,075.3%  
Net Cashflow Rs m11,110212 5,252.8%  

Share Holding

Indian Promoters % 52.9 71.5 74.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 7.0 57.0%  
FIIs % 26.6 12.6 211.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.8 187.5%  
Shareholders   93,274 26,511 351.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 23, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS